Clinical trial
Efficacy and Safety Study of Benralizumab Added to High-dose Inhaled…
NCT01928771 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT01928771 |
|---|---|
| Title | Efficacy and Safety Study of Benralizumab Added to High-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma |
| Official title | A Multicentre, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III Efficacy and Safety Study of Benralizumab (MEDI-563) Added to High-dose Inhaled Corticosteroid Plus Long-acting β2 Agonist in Patients With Uncontrolled Asthma |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Asthma |
| Intervention type | Biological |
| Interventions | Benralizumab, Placebo |
| Enrollment | 2,681 |
| Start date | Sep 19, 2013 |
| Primary completion | Apr 5, 2016 |
| Completion | Apr 5, 2016 |
| First posted | Aug 27, 2013 |
| Last update posted | May 3, 2017 |
| Countries | Australia, Brazil, Bulgaria, Czechia, France, Italy, Mexico, Peru, Poland, Russia, South Africa, South Korea and 5 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: